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Fibroblasts constitute an important source of cyto-
kines during in¯ammatory processes in the skin.
Interleukin-1 is a potent, pleiotropic cytokine that is
induced in activated human dermal ®broblasts.
Interleukin-1 further induces many in¯ammatory
mediators, including the chemokine interleukin-8.
As ®broblasts express both interleukin-1 and the
interleukin-1 receptor complex, the cellular response
may be enhanced by autocrine activation.
Interleukin-1a and interleukin-1b lack a signal pep-
tide and are translocated at the plasma membrane
using an alternative secretory pathway, which may
involve ATP-binding cassette transporter proteins.
We hypothesize that inhibition of this pathway pre-
vents secretion of interleukin-1, thereby downregu-
lating interleukin-1-dependent autocrine induction of
interleukin-8. We used the ATP-binding cassette 1
transporter inhibitor glybenclamide, which has been
previously shown to block interleukin-1b secretion in
human monocytes. Using enzyme-linked immuno-
sorbent assay, we assessed the effect of glybencla-
mide on interleukin-8 production in human dermal
®broblasts. In interleukin-1b-transfected human der-
mal ®broblasts, interleukin-8 was induced through
an autocrine activity of interleukin-1b.
Glybenclamide disabled this activation loop and sig-
ni®cantly reduced interleukin-8. In human dermal
®broblasts that were stimulated with tumor necrosis
factor a to reach high interleukin-1 expression levels,
glybenclamide similarly suppressed interleukin-8. In
contrast, glybenclamide did not affect interleukin-8
production in cells stimulated with interleukin-1
only. Glybenclamide did not affect caspase-1 in
®broblasts, which was expressed as an inactive pre-
cursor form, irrespective of treatments with tumor
necrosis factor a and/or glybenclamide. Using over-
expressing, interleukin-1-transfected COS-1 cells,
inhibition of interleukin-1a and interleukin-1b secre-
tion was directly demonstrated on Western blots.
These results are consistent with glybenclamide
preventing externalization of interleukin-1 and sub-
sequent autocrine induction of interleukin-8 in
human dermal ®broblasts. Acting through such a
mechanism, ATP-binding cassette transporter inhibi-
tors may downregulate in¯ammation locally.
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kines/glyburide/in¯ammation. J Invest Dermatol 117:871±
876, 2001
F
ibroblasts constitute a large pool of resident cells in skin,
which are an important source for cytokines early in
in¯ammation, before leukocytes have been attracted to
the site. Interleukin-1a (IL-1a) and IL-1b are induced in
®broblasts upon exposure to pro-in¯ammatory cyto-
kines, such as tumor necrosis factor a (TNF-a), or IL-1 itself. IL-1
is a very potent cytokine. Typically, IL-1 concentrations in the pM
range induce a robust response in many cell types, triggering the
production of multiple in¯ammatory mediators, including chemo-
kines. These in turn attract leukocytes, which further amplify the
in¯ammatory reaction (Dinarello, 1996; Karmiol and Phan, 1997;
Cullinan et al, 1998). IL-1 mRNA and protein expression is tightly
regulated at the level of transcription, mRNA stability, and
translation. In addition, IL-1a and IL-1b are post-translationally
modi®ed by the processing enzymes calpain and caspase-1,
respectively (Dinarello, 1996).
IL-1a and IL-1b both act via the same receptor complex,
consisting of IL-1 receptor type I, the ligand binding subunit, and
IL-1 receptor accessory protein (IL-1RAcP), the signaling subunit.
In ®broblasts, IL-1 induces several intracellular signaling pathways
that lead to the expression of proteases, prostaglandins, cytokines,
and chemokines. Activated ®broblasts express IL-1, which can bind
to and activate IL-1 receptors on the same cells in an autocrine
fashion. Through this mechanism, ®broblasts could trigger and
amplify a local in¯ammatory response.
Although IL-1 primarily acts as an extracellular cytokine, both
IL-1a and IL-1b lack a signal peptide and thus are not secreted
along the classical pathway through the endoplasmic reticulum and
Golgi apparatus (Rubartelli et al, 1990). An alternative secretory
pathway has been proposed that may involve transporters of the
ATP binding cassette (ABC) transporter family. In eukaryotes as
well as prokaryotes, ABC transporters translocate a wide range of
different substrates across cell membranes by an energy-dependent
mechanism (Broccardo et al, 1999; Klein et al, 1999). As many as
Manuscript received November 13, 2000; revised March 7, 2001;
accepted for publication May 2, 2001.
Reprint requests to: Dr. Matthias Bickel, Laboratory of Oral Cell
Biology, University of Bern, Freiburgstrasse 7, Postfach 64, CH-3010 Bern
10, Switzerland. Email: bickel@zmk.unibe.ch
Abbreviations: ABC, ATP-binding cassette; COS-1 cells, African green
monkey kidney cells (CV1 origin SV40); HDF, human dermal ®broblasts.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
871
®fty different ABC transporter genes are estimated to exist in
humans. Glybenclamide is a known potent inhibitor of ABC1, a
member of the ABCA subclass. Using expression of ABC1 in
Xenopus laevis oocytes, this compound almost completely blocked
ABC1 transporter activity (Becq et al, 1997). It has been suggested
that ABC1 is involved in IL-1 secretion, as glybenclamide also
blocked the secretion of IL-1b in human monocytes (Hamon et al,
1997; Andrei et al, 1999).
IL-1 is thought to play a role in several in¯ammatory conditions
of the skin, such as contact and atopic dermatitis (Junghans et al,
1998; Murphy et al, 2000; Ulfgren et al, 2000). IL-1b-de®cient
mice display impaired contact hypersensitivity (Shornick et al,
1996), whereas mice that overexpress IL-1a in the epidermis
develop spontaneous focal cutaneous in¯ammation (Groves et al,
1995). Speci®c inhibition of IL-1 leads to an attenuation of
in¯ammatory processes. Recombinant IL-1 receptor antagonist
(IL-1RA) is an ef®cacious treatment of arthritis, or endotoxin
shock, but must be given at large doses due to its low af®nity
towards IL-1 receptors (Burger et al, 1995; Ohlsson et al, 1990;
Dinarello, 1996; Joosten et al, 1999). Transgenic mice that
overexpress IL-1 receptor type II, a nonsignaling ``decoy receptor'',
in the epidermis display a weaker in¯ammatory response in the skin
(Rauschmayr et al, 1997). Thus, antagonizing IL-1 activity is a
promising way to downregulate in¯ammation in the skin.
We hypothesized that ABC transporter inhibitors, as suppressors
of IL-1 secretion, could interfere with IL-1-mediated autocrine
activation in ®broblasts. Using IL-1b-transfected ®broblasts, we
describe autocrine induction of IL-8. In this system, glybenclamide
inhibited IL-8 production. We corroborated the inhibitory effect of
glybenclamide in ®broblasts that were stimulated with TNF-a to
express endogenous IL-1. Finally, we used transfected African
green monkey kidney cells (CV1 origin SV40) (COS-1) cells
overexpressing either IL-1a or IL-1b to directly demonstrate the
inhibition of IL-1 secretion by glybenclamide.
MATERIALS AND METHODS
Cell culture, expression plasmids, transfection Primary human
dermal ®broblasts (HDF), established from a surgical specimen of a 6-y-
old boy, were kindly provided by Dr. Ulrich Wiesmann, University of
Bern, Switzerland. COS-1 cells were a kind gift of Dr. Erwin Sterchi,
Institute of Biochemistry and Molecular Biology, University of Bern.
HDF and COS-1 cells were cultured in HEPES-buffered (25 mM)
minimum essential medium (Gibco BRL Life Technologies, Paisley,
U.K.), supplemented with 10% fetal bovine serum (Seromed/Biochrom,
Berlin, Germany), 2 mM glutamine, and antibiotics (100 IE per ml
penicillin, 100 mg per ml streptomycin). Non-essential amino acids
(100 mM each) were additionally supplied to the medium for HDF
cultures. HDF were used at passages below 20.
Plasmids containing full-length cDNAs for human IL-1a and IL-1b
(GenBank accession numbers M15329 and M15330) (Nishida et al, 1987)
were kindly provided by Dr. Christoph MuÈller, Institute of Pathology,
University of Bern. Coding sequences were ampli®ed by polymerase
chain reaction (PCR) using primers that included BamHI restriction sites
and were cloned into the eukaryotic expression vector pSG5 (Stratagene,
La Jolla, CA). Primers were GAC ATG GAT CCA AAG AAG TCA
AGA GGC/GTT AAG GAT CCT ACG CCT GGT TTT CCA G for
IL-1a, and GAC ATG GAT CCG CAG CCA TGG CAG AAG TAC
C/GTT AAG GAT CCT TAG GAA GAC ACA AAT TGC for IL-1b.
IL-1 coding regions in vector constructs were veri®ed by sequencing.
HDF were transfected using Effectene (Qiagen, Basel, Switzerland)
according to the manufacturer's instructions. COS-1 cells were trans-
fected using diethylaminoethyl dextran as described previously
(Dumermuth et al, 1993). Transfection ef®ciency was monitored using
green ¯uorescent protein (Stauber et al, 1998) (plasmid GFPsg25 was a
gift from Dr. Volker Heussler, Institute of Animal Pathology, University
of Bern).
Treatment of cell cultures with cytokines, antibodies, and
glybenclamide One day after transfection, ®broblasts were incubated
overnight with either of the following agents: neutralizing anti-IL-1b
monoclonal antibody (MAB601), IL-1RA (both from R&D Systems,
Abingdon, U.K.), glybenclamide [Sigma, St. Louis, MI, prepared as a
100 mM stock solution in dimethylsulfoxide (DMSO)]. In a separate set
of experiments, glybenclamide was added to con¯uent HDF cultures that
were stimulated for 24 h with 10 ng per ml TNF-a (Peprotech,
London, U.K.) or 1 ng per ml IL-1a (R&D Systems). TNF-a treatment
was initiated overnight, and cells were subsequently incubated with
glybenclamide in the continuous presence of the cytokine. In IL-1a-
treated cells, glybenclamide was present over the whole 24 h incubation
period. Where glybenclamide was used, DMSO was adjusted to the same
concentration in the culture medium, never exceeding 0.8%.
Supernatants were collected and supplemented with protease inhibitors (1
mM phenylmethylsulfonyl ¯uoride, 200 mg per ml pepstatin, 200 mg per
ml aprotinin, 1 mg per ml leupeptin, 3.5 mg per ml benzamidine, from
Sigma). Cells were harvested in cell culture lysis reagent (Promega,
Madison, WI) containing protease inhibitors. To exclude a cytotoxic
effect of glybenclamide and/or DMSO, lactate dehydrogenase (LDH)
activities were measured in cell supernatants.
Enzyme-linked immunosorbent assay (ELISA) ELISA for IL-8
and IL-1b were performed using a matched pair of antibodies (R&D
Systems): anti-IL-8 MAB208 and anti-IL-1b MAB601 primary
antibodies were used in combination with biotinylated secondary
antibodies. Bound antibody was detected using streptavidin peroxidase
(Southern Biotechnology Associates, Birmingham, AL) and ABTS
(Sigma) as chromogenic substrate. Samples were measured in double
from multiple dilutions and quanti®ed against standard curves obtained
with recombinant cytokines (standard 10 ng per ml to 14 pg per ml).
Western blot For IL-1a and IL-1b, equal amounts of cell lysates
(100 ng protein) and supernatants (10 ml) from IL-1a- and IL-1b-
transfected COS-1 cells were separated by 14% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions and blotted onto PVDF membrane. For caspase-1, protein
extracts (100 mg) from HDF treated with TNF-a and/or glybenclamide
and from control HDF were separated by 12% SDS-PAGE. Membranes
were blocked with 5% skim milk in isotonic Tris-buffered saline,
pH 7.4, and incubated with either antihuman IL-1a polyclonal antibody
(Peprotech), antihuman IL-1b monoclonal antibody (MAB601, R&D
Systems), or antihuman caspase-1 polyclonal antibody (Santa Cruz), and
corresponding peroxidase-coupled anti-IgG polyclonal antibody
(AmershamPharmaciaBiotech). Immunoreactive protein bands were
visualized onto radiographic ®lms using enhanced chemiluminescence
(SuperSignal West Femto, Pierce, Rockford, IL). Densitometric
measurements were performed on digitized radiographs using the image
analysis software Gel-Base/GelBlot-Pro (Synoptics, Cambridge, U.K.).
Caspase-1 assay Caspase-1 activity in HDF was measured using a kit
from R&D Systems. This assay is based on the speci®c peptide substrate
WEDH-p-nitroanilide.
RESULTS
IL-1b-transfected ®broblasts release IL-8 As treatment of
®broblasts with exogenous IL-1b induces IL-8, these cells may
enhance IL-8 expression through the autocrine activity of
endogenously expressed IL-1b. To demonstrate such a
mechanism, we transfected HDF with the IL-1b precursor
and monitored the consecutive daily IL-8 production. IL-1b
protein expression in IL-1b-transfected cells peaked after 3±4 d.
In marked contrast, IL-1b was hardly expressed in vector-
transfected control cells (Fig 1A). Protein concentration in cell
extracts did not differ between IL-1b- and vector-transfected
cell populations (not shown), indicating that cell densities were
similar. IL-1b-transfected HDF released nine to 20 times more
IL-8 than vector-transfected control cells (Fig 1B), reaching a
maximum after 3±4 d, coincident with maximum IL-1b
expression. Incubation with IL-1RA or neutralizing antibodies
against IL-1b led to a 75% reduction of IL-8 (Fig 1B, inset).
Thus, IL-1b is present extracellularly as a soluble or cell-
surface-associated molecule to allow induction of IL-8 in an
autocrine fashion. In the medium, IL-1b was only detectable 3 d
after transfection at concentrations close to the detection limit
of the ELISA used (15 pg per ml, not shown).
Glybenclamide reduces IL-8 production in IL-1b-
transfected and TNF-a-treated ®broblasts The ABC1
transporter inhibitor glybenclamide, as a suppressor of IL-1b
secretion (Becq et al, 1997), dose-dependently reduced IL-8
production in IL-1b-transfected ®broblasts (Fig 2B). After an
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overnight incubation with 100 mM glybenclamide, IL-8 in the
supernatant was 40% compared to IL-1b-transfected control cells.
In contrast, glybenclamide did not affect IL-8 levels in supernatants
of cells that were transfected with vector alone (13% and 12% in the
presence of 100 mM glybenclamide and DMSO, respectively). IL-8
was not detectable in cellular extracts, indicating that IL-8 did not
accumulate intracellularly and was secreted ef®ciently in the
presence of glybenclamide (not shown), con®rming previous
®ndings that glybenclamide does not affect secretion of proteins
along the classical pathway (Hamon et al, 1997). Thus, reduction of
IL-8 in the supernatant by glybenclamide is attributable to
decreased production. Slightly decreased cellular IL-1b levels
were observed in the presence of the highest glybenclamide dose
(Fig 2).
HDF were treated overnight with TNF-a, which strongly
induces IL-1b concomitantly with IL-8 (Sporri et al, 1998).
Subsequent incubation with glybenclamide dose-dependently
reduced IL-8 production, revealing a similar inhibitory pattern as
in IL-1b-transfected cells (Fig 3A). In the presence of 100 mM
glybenclamide, IL-8 in the supernatant was 58% compared to
control cells. The inhibitory effect of glybenclamide was not
restricted to IL-8, as IL-6 was reduced to a similar extent (not
shown). Glybenclamide did not cause unspeci®c hyporesponsive-
ness in HDF, however. In a control experiment, glybenclamide-
treated cells were stimulated with exogenous IL-1 (1 ng per ml),
which is expected to override autocrine stimulation from
endogenous IL-1. These cells produced similar amounts of IL-8
compared to control cells. As a cytotoxic assay, we further
determined LDH activities in cell culture supernatants. No
signi®cant LDH activity could be detected in either control HDF
or HDF treated with glybenclamide and/or TNF-a, excluding an
unspeci®c inhibitory effect of glybenclamide on IL-8 production
due to cytotoxicity.
An important regulatory step for IL-1b is thought to be the
processing and concomitant activation of the precursor form by
caspase-1 (Black et al, 1989; Kostura et al, 1989). We therefore
investigated the effect of glybenclamide on the expression and
activity of caspase-1 in HDF. Caspase-1 was expressed in ®broblasts
exclusively as a 35 kDa precursor form (Fig 3B), irrespective of
treatments with TNF-a and/or glybenclamide. Accordingly, no
caspase-1 activity was detected in cell lysates using a speci®c
chromogenic peptide substrate (not shown).
Glybenclamide inhibits secretion of IL-1a and IL-1b in
transfected COS-1 cells As IL-1 in the supernatant was hardly
detectable in ®broblasts, we used COS-1 cells transfected with
IL-1a or IL-1b precursors to directly demonstrate inhibition of
IL-1 secretion by glybenclamide in an overexpressing system
(Fig 4). On Western blots, the IL-1a precursor (34±35 kDa) was
expressed in cell lysates, whereas the processed mature form
(18 kDa) appeared in supernatants (Fig 4A). As mature IL-1a was
not detected in cell lysates, processing of IL-1a probably occurred
concomitantly with its secretion. In contrast, IL-1b was not
processed and was secreted as the 33 kDa precursor form (Fig 4B).
Cleavage of IL-1a and IL-1b precursors by calpain and caspase-1 is
cell type speci®c, however, depending on the expression and
activity of these processing enzymes.
Independently from processing, glybenclamide (100 mM) in-
hibited the secretion of both mature IL-1a and IL-1b precursor,
whereas cellular IL-1 levels remained unchanged (Fig 2A, B, lanes
2, 3). Densitometric analysis revealed that signals for mature IL-1a
and IL-1b precursor in supernatants of glybenclamide-treated cells
relative to control cells were 51% and 41%, respectively.
Measurements of IL-1a and IL-1b in supernatants using ELISA
con®rmed these results, showing reductions to 34% and 51%,
respectively, in glybenclamide-treated cells (100 mM) relative to
control cells. On the other hand, brefeldin, an inhibitor of the
``classical'' secretory pathway, did not reduce secretion of IL-1a or
IL-1b in transfected COS-1 cells (not shown), which is in
accordance with a previous study using monocytes (Rubartelli et
al, 1990).
DISCUSSION
In primary human dermal ®broblasts, IL-1b acts as an autocrine
factor to enhance expression of IL-8. The expression of several
other genes depends on the autocrine activity of IL-1 in ®broblasts,
such as hepatocyte growth factor, stromelysin, Mn-superoxide
dismutase, and collagenase. Furthermore, TNF-a-treated ®bro-
blasts express less IL-6 in the presence of neutralizing antibodies
against IL-1 receptor. Similarly, IL-1RAcP-de®cient ®broblasts,
which cannot respond to IL-1, also display reduced IL-6 expression
levels upon TNF-a treatment, indicating that gene induction by
TNF-a in ®broblasts in part depends on the autocrine activity of
IL-1 (Kumar et al, 1992; West-Mays et al, 1995; Cullinan et al,
1998; Miyazaki et al, 1998).
Figure 1. Interleukin-8 is induced in IL-1b-transfected human
primary ®broblasts. HDF were transfected with the expression vector
pSG5 containing the coding sequence of the IL-1b precursor under the
control of an SV40 promoter (closed symbols) or with vector alone (open
symbols). Using ELISA, IL-1b and IL-8 were measured in cells and
supernatants over 2±6 d after transfection. (A) IL-1b expression in cells.
(B) Daily release of IL-8. Inset: Inhibition of IL-8 production in the
presence of IL-1RA (25 ng per ml) and anti-IL-1b monoclonal antibody
(10 mg per ml) relative to control cells. Results shown are representative
for experiments repeated three times.
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Published data suggest that, in contrast to human monocytes,
®broblasts do not secrete IL-1 (Fuhlbrigge et al, 1988; Young et al,
1988). We also did not detect IL-1 in the medium of TNF-a-
treated HDF, and IL-1b was hardly detectable in the medium of
transfected HDF. At ®rst glance, these ®ndings are in con¯ict with
IL-1 as an autocrine factor in ®broblasts. IL-1 does not need to be
present as a soluble factor in order to activate neighboring cells,
however. Using biochemical methods, biologic assays, ¯uores-
cence-activated cell sorting, or immunoelectron microscopy, IL-1a
and IL-1b have been demonstrated to be localized on the plasma
membrane (Kurt-Jones et al, 1985; Brody and Durum, 1989; Zola
et al, 1993; Singer et al, 1995; Fukushima et al, 1997). Using binding
studies with radiolabeled soluble IL-1 receptor, it has been
estimated that 1000 high af®nity sites per cell reside on the plasma
membrane of TNF-a-treated ®broblasts (Sporri et al, 1998).
Therefore, cell surface-associated IL-1 on ®broblasts could be
engaged in cell-contact-dependent cell activation.
In transfected COS-1 cells glybenclamide inhibited the secretion
of both IL-1a and IL-1b. In contrast to our data, it has been
described previously that only secretion of IL-1b, but not of IL-1a,
was impaired in glybenclamide-treated monocytes (Hamon et al,
1997). This suggests that (i) several ABC transporters might be
capable of IL-1a and/or IL-1b translocation, (ii) speci®c cell types
could be equipped with different sets of ABC transporters, and (iii)
regulation of ABC transporters could differ from one cell type to
another.
It remains to be resolved which ABC transporter(s) translocate
IL-1a and IL-1b. Recently, several mutations in the ABC1
transporter have been identi®ed to cause Tangier disease in humans
(Bodzioch et al, 1999; Brooks-Wilson et al, 1999; Lawn et al, 1999;
Remaley et al, 1999; McNeish et al, 2000). Interestingly, secretion
of IL-1 is not impaired in these patients (G. Schmitz, personal
communication). Glybenclamide may also inhibit other ABC
transporters. As glybenclamide did not completely block secretion
of IL-1a and IL-1b in COS-1 cells (Fig 4), alternative IL-1
transport systems may exist.
Glybenclamide did not change the expression or activation of
caspase-1 in ®broblasts. In fact, only a 33 kDa form of caspase-1 was
detected in ®broblasts, and processing to activated forms was not
induced by TNF-a or glybenclamide. Furthermore, no activity for
caspase-1 was detected using a speci®c chromogenic peptide
substrate. The 33 kDa form thus corresponds to one of the
Figure 3. Glybenclamide reduces IL-8 production in TNF-a-
stimulated primary ®broblasts, but does not change caspase-1
expression. (A) Con¯uent HDF cultures were stimulated for 24 h with
10 ng per ml TNF-a (black bars), or with 1 ng per ml IL-1a (white bars)
in the presence of glybenclamide, or with solvent alone. IL-8 production
of TNF-a- and IL-1a-treated cells in the presence of glybenclamide is
expressed relative to respective cytokine-treated cells without
glybenclamide. Results shown are representative for experiments
repeated three times. n.d., not done. (B) Western blot for caspase-1. Cell
extracts of HDF (100 mg protein, lanes 1±6) and human macrophages
(20 mg protein, lanes 7, 8) were immunoblotted for caspase-1. Some cells
were cultured overnight with 10 ng per ml TNF-a (lanes 4±6) or with 1
mg per ml lipopolysaccharide (lane 8). HDF were treated with 10 mM
(lanes 2, 5), or 100 mM glybenclamide, or with DMSO as a control
(lanes 1, 4). Arrow indicates the activated form of caspase-1 (p20) in
human macrophages treated with lipopolysaccharide (lane 8).
Figure 2. Glybenclamide reduces IL-8 production in IL-1b-
transfected ®broblasts. HDF were transfected with IL-1b (pSG5±IL-
1b), with vector alone (pSG5), or were processed for transfection
without addition of DNA (none). The following day, media were
changed, and cells were incubated overnight with glybenclamide at
indicated concentrations, or with DMSO alone. IL-1b in cells (A) or
IL-8 levels in supernatants (B) are given as relative values compared to
IL-1b-transfected cells incubated without glybenclamide. n.d. = not
detectable. IL-1b was not detectable in cells transfected with vector
alone. Experiments were repeated three times, and a representative
example is shown.
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previously described inactive precursor forms, which range from 45
to 30 kDa (Alnemri, 1995). IL-1b in ®broblasts may be processed
independently of caspase-1, however. Such an alternative process-
ing pathway was proposed in a report on caspase-1 knockout mice
(Li, 1997): these animals are still able to produce residual amounts
of mature IL-1b.
Glybenclamide is widely used as an antidiabetic drug in patients
with type II diabetes. Therapeutic glybenclamide concentrations in
the serum of diabetic patients in vivo are well below the concen-
trations necessary to inhibit ABC1 transporters in vitro. Clearly,
induction of insulin secretion via the sulfonylurea receptor and
membrane depolarization (Boyd et al, 1991; Aguilar-Bryan et al,
1995) occurs independently from inhibition of ABC1 transporters
(Becq et al, 1997). Glybenclamide, as a suppressor of IL-1 secretion,
interrupts IL-1-mediated autocrine activation in ®broblasts, redu-
cing the expression of IL-8 and possibly other IL-1 inducible pro-
in¯ammatory genes, including IL-1 itself. From this point of view,
glybenclamide might have anti-in¯ammatory properties.
Interestingly, IL-18, another member of the IL-1 family, also lacks
a signal peptide, and therefore could also be secreted via ABC
transporters. Could more potent and speci®c ABC transporter
inhibitors become a new group of anti-in¯ammatory drugs?
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